ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

Featured Stories

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

View Our Video
Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

View the data
I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View the portrait series

In the News

Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer

November 16th, 2022|

The LESS study will evaluate reduced endocrine therapy for HR+/HER2- patients with MammaPrint® Ultra Low tumors to improve quality of life without compromising outcomes Study strengthens Agendia’s growing global footprint in breast cancer to inform Read More

Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments

June 4th, 2022|

Data demonstrate Research Use Only ImPrint test’s ability to identify patients with high risk early breast cancer who may benefit from PD-1/PD-L1 checkpoint inhibition IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS - June 4, 2022 – Read More

Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer

May 25th, 2022|

Company to present multiple recent Registry sub-studies driving cancer care innovation at ASCO 2022 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 25, 2022 – Agendia, Inc., a commercial-stage company focused on improving outcomes for Read More